Clinical effect of Zhilong Huoxue Tongyu capsules in treatment of chronic heart failure with Qi deficiency and blood stasis:An analysis of 51 cases
Objective:To investigate the clinical effect of Zhilong Huoxue Tongyu capsules in the treatment of chro-nic heart failure(CHF)with Qi deficiency and blood stasis and its association with NOD-like receptor protein 3(NLRP3)inflammasome.Methods:A total of 108 CHF patients with Qi deficiency and blood stasis were enrolled and di-vided into treatment group and control group using a random number table at a ratio of 1∶1,with 54 patients in each group.The patients in the control group received conventional Western medicine basic treatment and metoprolol succinate sus-tained-release tablets,while those in the treatment group received Zhilong Huoxue Tongyu capsules in addition to the treat-ment in the control group,and the course of treatment was 30 days for both groups.Clinical outcome was compared between the two groups,as well as traditional Chinese medicine(TCM)syndrome score,NYHA class of left heart function,echocar-diography parameters(left ventricular ejection fraction[LVEF],left ventricular end-systolic diameter[LVESD],and stroke volume[SV]),and the levels of N-terminal pro-brain natriuretic peptide(NT-ProBNP),NLRP3,interleukin-1β(IL-1β),and interleukin-18(IL-18)before and after treatment,and safety was assessed for both groups.The correlation of CHF severity with NLRP3,IL-1β,and IL-18 was analyzed.Results:During the study,3 patients in the treatment group and 3 in the control group were lost to follow-up,and finally 102 patients were included in the analysis of treatment out-come,with 51 patients in each group.There was a significant difference in overall response rate between the treatment group and the control group[94.12％(48/51)vs 88.24％(45/51),P＜0.05].After treatment,both groups had signifi-cant changes in TCM syndrome score,NYHA class of left heart function,echocardiography parameters,and the levels of NT-ProBNP,NLRP3,IL-1β,and IL-18,and there were significant differences in these indicators between the two groups after treatment(P＜0.05).No serious adverse event was observed in either group.The Pearson correlation analysis showed that for both groups,the expression levels of NLRP3,IL-1β,and IL-18 before treatment were positively correlated with TCM syndrome score,NT-ProBNP,and LVESD before treatment and were negatively correlated with LVEF and SV before treatment.Conclusion:Zhilong Huoxue Tongyu capsules can safely and effectively improve the clinical symptoms and cardi-ac function of CHF patients with Qi deficiency and blood stasis,with a marked clinical effect,possibly by inhibiting NLRP3 inflammasome,IL-1β,and IL-18 in serum.
chronic heart failureQi deficiency and blood stasis syndromeZhilong Huoxue Tongyu capsulesNOD-like receptor protein 3 inflammasome
万方数据
维普
